Skip header and navigation
CMA PolicyBase

Policies that advocate for the medical profession and Canadians


4 records – page 1 of 1.

Prelicensure clinical training programs

https://policybase.cma.ca/en/permalink/policy565
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Health human resources
Resolution
GC87-67
That provision should be made for enough flexibility within prelicensure clinical training programs to prepare physicians for a variety of practice situations in Canada (eg. rural, isolated, urban) without undue prolongation of the training period.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Health human resources
Resolution
GC87-67
That provision should be made for enough flexibility within prelicensure clinical training programs to prepare physicians for a variety of practice situations in Canada (eg. rural, isolated, urban) without undue prolongation of the training period.
Text
That provision should be made for enough flexibility within prelicensure clinical training programs to prepare physicians for a variety of practice situations in Canada (eg. rural, isolated, urban) without undue prolongation of the training period.
Less detail

Specialty training for family medicine residents

https://policybase.cma.ca/en/permalink/policy572
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Health human resources
Resolution
GC87-66
That appropriate training in speciality areas of medicine be provided to family medicine residents within the existing two years of the residency training program where possible.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Health human resources
Resolution
GC87-66
That appropriate training in speciality areas of medicine be provided to family medicine residents within the existing two years of the residency training program where possible.
Text
That appropriate training in speciality areas of medicine be provided to family medicine residents within the existing two years of the residency training program where possible.
Less detail

Adverse reactions between alcohol and drug products

https://policybase.cma.ca/en/permalink/policy805
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-31
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Text
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Less detail

Drug product substitution

https://policybase.cma.ca/en/permalink/policy806
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Policy Type
Policy resolution
Last Reviewed
2017-03-04
Date
1987-08-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
GC87-39
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Text
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Less detail